Artivion price target raised to $30 from $28 at Stifel

Stifel raised the firm’s price target on Artivion to $30 from $28 and keeps a Buy rating on the shares. Artivion’s AMDS aortic repair technology’s PERSEVERE U.S. pivotal trial is approaching 12-month follow-up completion in November, notes the analyst, who adds that a positive outcome would help unlock a roughly $150M U.S. AMDS total addressable market opportunity.